Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박병배 | - |
dc.date.accessioned | 2018-02-02T07:40:53Z | - |
dc.date.available | 2018-02-02T07:40:53Z | - |
dc.date.issued | 2011-02 | - |
dc.identifier.citation | INVESTIGATIONAL NEW DRUGS, v. 29, NO 1, Page. 154-160 | en_US |
dc.identifier.issn | 0167-6997 | - |
dc.identifier.issn | 1573-0646 | - |
dc.identifier.uri | http://link.springer.com/article/10.1007%2Fs10637-009-9320-y | - |
dc.identifier.uri | http://hdl.handle.net/20.500.11754/35076 | - |
dc.description.abstract | Background: We investigated response rates to and toxicities of gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for the treatment of relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). Patients and Methods: Patients with recurrent or refractory diffuse large B-cell lymphoma or mantle cell lymphoma (DLBCL) were eligible for enrollment in this study. Treatment consisted of gemcitabine 1,000 mg/m(2) intravenously (i.v.) on Days 1 and 8, ifosfamide 2,000 mg/m(2) i.v. on Day 1, dexamethasone 40 mg orally on Days 1-4, and oxaliplatin 130 mg/m(2) i.v. on Day 2, every 21 days. The primary goal of treatment was to establish a response rate after three cycles. Afterwards, patients could proceed to high-dose chemotherapy followed by autologous stem cell transplantation (HDC-ASCT) or receive up to six treatment cycles. Results: Twenty-seven eligible patients were evaluated for toxicity and response. The median age of the patients was 54 years (range, 18-75 years), and most had DLBCL. After three cycles, there were four CR (15%) and 10 PR (37%) for an overall response rate (RR) of 52%. Among a total of 88 GIDOX cycles, grade 3 and 4 neutropenia occurred in 33% and 16% of the cycles, respectively. Likewise, grade 3 and 4 thrombocytopenia occurred in 14% and 16% of the cycles, respectively. Two patients (2%) experienced febrile neutropenia, while seven patients (26%) proceeded to HDC-ASCT. Conclusions: GIDOX is an active salvage regimen for aggressive B-cell NHL and can be tolerated by patients with acceptable toxicity. | en_US |
dc.language.iso | en | en_US |
dc.publisher | SPRINGER | en_US |
dc.subject | Gemcitabine | en_US |
dc.subject | Salvage therapy | en_US |
dc.subject | Non-Hodgkin's lymphoma | en_US |
dc.title | Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin's lymphoma: a consortium for improving survival of lymphoma (CISL) trial | en_US |
dc.type | Article | en_US |
dc.relation.no | 1 | - |
dc.relation.volume | 29 | - |
dc.identifier.doi | 10.1007/s10637-009-9320-y | - |
dc.relation.page | 154-160 | - |
dc.relation.journal | INVESTIGATIONAL NEW DRUGS | - |
dc.contributor.googleauthor | Park, Byeong-Bae | - |
dc.contributor.googleauthor | Kim, Won Seog | - |
dc.contributor.googleauthor | Eom, Hyeon Seok | - |
dc.contributor.googleauthor | Kim, Jin Seok | - |
dc.contributor.googleauthor | Lee, Young Yiul | - |
dc.contributor.googleauthor | Oh, Suk Joong | - |
dc.contributor.googleauthor | Lee, Dae Ho | - |
dc.contributor.googleauthor | Suh, Cheolwon | - |
dc.relation.code | 2011204426 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | bbpark | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.